PubRank

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Clinical Trial ID NCT02335918

PubWeight™ 11.98‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02335918

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers (Basel) 2015 0.90
2 New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2015 0.89
3 Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother 2016 0.89
4 Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol 2016 0.87
5 Principles of antibody-mediated TNF receptor activation. Cell Death Differ 2015 0.84
6 Advances in immunotherapy for melanoma. BMC Med 2016 0.83
7 Novel therapeutic agents in the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2016 0.83
8 Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy 2015 0.81
9 Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag 2016 0.81
10 Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016 0.81
11 The emerging role of immunotherapy in colorectal cancer. Ann Transl Med 2016 0.80
12 Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res 2015 0.78
13 Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. Front Oncol 2016 0.77
14 Current clinical immunotherapeutic approaches for head and neck cancer. F1000Res 2016 0.75
15 Immunotherapy in human colorectal cancer: Challenges and prospective. World J Gastroenterol 2016 0.75
Next 100